1) Strategic Imperatives and Leadership Transition - Viatris reported a strong start to 2026, with a focus on three strategic imperatives: driving the base business, fueling innovation, and modernizing for sustainable growth. - The leadership team, including new Interim CFO Paul Campbell, is expected to maintain operational discipline and continuity during the transition. - The company is committed to capital allocation that balances returning capital to shareholders and investing in growth opportunities.

2) Financial Performance and Segment Results - Total revenues for Q1 2026 were $3.5 billion, representing a 3% YoY increase. - Adjusted EBITDA was reported at $1 billion, with adjusted EPS of $0.59 per share. - Segment performance highlights: - North America: Grew 3%, driven by increased demand for estradiol and new complex generic launches. - Europe: Declined by 1% due to competitive pressures and supply constraints. - Greater China: Achieved 18% YoY growth, attributed to strong market fundamentals and strategic investments, particularly in e-commerce.

3) Pipeline Progress and Product Launches - Regulatory approval was achieved for EFFEXOR in Japan for generalized anxiety disorder, with additional product launches expected in the coming years. - Key upcoming regulatory decisions include: - XULANE LO (contraceptive patch) expected by July 30, 2026. - Fast-acting meloxicam anticipated in Q4 2026. - The company is also advancing its Phase III programs for selatogrel and cenerimod, with results expected in 2027.

4) Operational Challenges and Market Dynamics - Emerging markets faced flat net sales YoY, below expectations, due to supply constraints in the lower-margin ARV portfolio. - The European market is experiencing competitive pressure, particularly affecting products like Dymista. - The company is actively working to mitigate supply disruptions in its ARV business by diversifying production sources.

5) Guidance and Outlook - Viatris reaffirmed its guidance for 2026, expecting stronger growth in Greater China and a potential 1% tailwind from foreign currency rates. - The company anticipates that total revenues, adjusted EBITDA, and adjusted EPS will be weighted toward the second half of the year, reflecting normal seasonality and product launch timing. - The transcript did not provide specific figures for future quarters or detailed expectations for the impact of new product launches beyond 2026.

Bottom line: Viatris is off to a strong start in 2026, with solid revenue growth driven by strategic execution and a robust pipeline. The company is well-positioned for sustained growth, supported by disciplined capital allocation and a focus on innovative product launches, making it an attractive prospect for shareholders.